Liminatus Pharma, Inc. Class A Common Stock (LIMN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 14.49M |
| Enterprise Value | 15.59M |
| P/E Ratio | -0.28 |
| PEG Ratio | -0 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | -20.57 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -0.24 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
Profitability
| Profit Margin | 0 |
| Operating Margin | 0 |
AD
Management Effectiveness
| Return On Assets | -3.94 |
| Return On Equity | 2.16 |
Income Statement
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | 0 |
| EBITDA | -9.99M |
| Net Income | -10.21M |
| Diluted EPS | -0.43 |
Balance Sheet
| Total Cash | 1.91M |
| Total Cash/Share | 0.08 |
| Total Debt | 1.44M |
| Total Debt/Equity | -10.88 |
| Current Ratio | 0.96 |
| Book Value Per Share | -0.01 |
Price History
| 52-Week Change | -98.7 |
| 52-Week High | 10.75 |
| 52-Week Low | 0.1 |
| Moving Average 50 Days | 0.17 |
| Moving Average 200 Days | 0.66 |
Statistics
| Average Volume | 11.67M |
| Shares Outstanding | 26.83M |
| % Held by Institutions | 6.21 |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
